Cure8 research brief
People with IBD or other autoimmune diseases are often concerned that vaccines might work less well for them.
This study suggests influenza and zoster vaccines had similar effectiveness in people with MS, IBD, or inflammatory rheumatic disorders compared with those without AID, which supports vaccination in these groups.
Patients with IBD or other autoimmune diseases, clinicians advising on vaccinations, and researchers in vaccine effectiveness.
This study used German insurance claims data to emulate trials comparing vaccine effectiveness (VE) of herpes zoster and seasonal influenza vaccines between people with autoimmune/immune-mediated diseases (AID: multiple sclerosis, chronic inflammatory bowel disease, and chronic inflammatory rheumatic disorders) and those without AID.
Across the herpes zoster analysis (≈169,000 vaccinated and matched controls, ~11,000 AID people per group) and four influenza seasons (2015/16–2018/19; hundreds of thousands to >1.7 million people per season, tens of thousands with AID), the authors found no consistent or meaningful differences in VE between AID and non-AID groups after matching and adjustment.
The paper concludes that influenza and zoster vaccines appear similarly effective in people with MS, IBD, or CIRD in this claims-based analysis, but it notes the need for further study in other autoimmune conditions and infections.
Results come from emulated trials using insurance claims from Germany and are subject to limitations of observational claims data (residual confounding, coding accuracy, limited clinical detail). The study covered specific AID groups (MS, IBD, CIRD) and seasons; findings may not generalize to all autoimmune conditions or vaccine types.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests using both faecal calprotectin and intestinal ultrasound together can better identify patients who reach deeper, transmural healing — and those patients had lower risk of bowel-damage progression....
The study links symptom trajectories during the first year of biologic treatment to endoscopic remission, suggesting that week 20 symptom assessment may help predict long-term outcomes for people with UC on biologics.
AI-assisted capsule endoscopy may improve detection of Crohn’s disease lesions and reduce missed findings, which could affect diagnosis and monitoring. People with IBD may see faster or more consistent reads of capsule...
